NEW YORK (GenomeWeb) – Cancer diagnostics firm Signal Genetics lowered the amount it intends to raise from its proposed initial public offering to $9.3 million from a previous target of $25 million, it said in an amended preliminary prospectus filed with the US Securities and Exchange Commission on Thursday.

The company also lowered the amount of shares it plans to offer to 909,090 from about 2.3 million shares it said it would offer when it originally filed its Form S-1 in March.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.